{
    "root": "315baaa6-5129-f27b-e063-6294a90a2c91",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20250327",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV"
        }
    ],
    "indications": "phentermine hydrochloride , usp 37.5 mg indicated short-term ( weeks ) adjunct regimen weight reduction based exercise , behavioral modification caloric restriction management exogenous obesity patients initial body mass index greater equal 30 kg/m 2 , greater equal 27 kg/m 2in presence risk factors ( e.g . , controlled hypertension , diabetes , hyperlipidemia ) . chart body mass index ( bmi ) based various heights weights . bmi calculated taking patient ’ weight , kilograms ( kg ) , divided patient ’ height , meters ( ) , squared . metric conversions follows : pounds ÷ 2.2 = kg ; inches x 0.0254 = meters . limited usefulness agents class , including phentermine hydrochloride , [ pharmacology ( 12.1 , 12.2 ) ] measured possible risk factors inherent described .",
    "contraindications": "individualized obtain adequate response lowest effective dose . ( 2.1 ) late evening avoided ( risk insomnia ) . ( 2.1 ) phentermine hydrochloride taken without food . ( 2.1 ) limit 15 mg daily patients severe renal impairment ( egfr 15 29 ml/min/1.73 2 ) ( 2.2 )",
    "warningsAndPrecautions": "available tablets capsules containing 37.5 mg phentermine hydrochloride ( equivalent 30 mg phentermine base ) . phentermine hydrochloride tablets , usp 37.5 mg ( equivalent 30 mg phentermine base ) , supplied blue white mottled oval tablets debossed “ k ” left bisect “ 25 ” one side plain side . bottles 1000 , ndc 68071-3819-1 storeat 20° 25°c ( 68° 77°f ) , excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispensein tight , light resistant container defined usp/nf , child-resistant closure ( required ) . keep reach children",
    "adverseReactions": "history cardiovascular disease ( e.g . , coronary artery disease , stroke , arrhythmias , congestive heart failure , uncontrolled hypertension ) within 14 days following monoamine oxidase inhibitors hyperthyroidism glaucoma agitated states history abuse pregnancy [ ( 8.1 ) ] nursing [ ( 8.3 ) ] known hypersensitivity , idiosyncrasy sympathomimetic amines",
    "indications_original": "Phentermine hydrochloride, USP 37.5 mg is indicated as short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m\n \n  2, or greater than or equal to 27 kg/m\n \n  2in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n\n \n                  Below is a chart of Body Mass Index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.\n                  \n                     \n                  \n                  The limited usefulness of agents of this class, including Phentermine hydrochloride, [see\n \n  CLINICAL PHARMACOLOGY (\n  \n   12.1,\n  \n   12.2)\n \n  ] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications_original": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. ( 2.1 ) Late evening administration should be avoided (risk of insomnia). ( 2.1 ) Phentermine Hydrochloride can be taken with or without food. ( 2.1 ) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) ( 2.2 )",
    "warningsAndPrecautions_original": "Available in tablets and capsules containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg Phentermine base).\n                  Phentermine hydrochloride tablets, USP 37.5 mg (equivalent to 30 mg phentermine base), are supplied as blue and white mottled oval tablets debossed “K” left to bisect “25” on one side and plain on the other side.\n                  \n                  Bottles of 1000, NDC 68071-3819-1\n                  \n                  \n                     Storeat 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].\n \n                  \n                     Dispensein a tight, light resistant container as defined in the USP/NF, with a child-resistant closure (as required).\n \n                  Keep out of the reach of children",
    "adverseReactions_original": "History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n                     During or within 14 days following the administration of monoamine oxidase inhibitors\n                     Hyperthyroidism\n                     Glaucoma\n                     Agitated states\n                     History of drug abuse\n                     Pregnancy [see\n  \n   Use in Specific Populations (\n   \n    8.1)\n  \n   ]\n \n  \n                     Nursing [see\n  \n   Use in Specific Populations (\n   \n    8.3)\n  \n   ]\n \n  \n                     Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines"
}